Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2014; 20(44): 16674-16682
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16674
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16674
Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats
Qing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
Jun-Jie Jiang, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
Peng-Tao Li, Xin-Yue Wang, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China
Author contributions: Du QH and Han L contributed equally to this work and are co-first authors in this study; Du QH, Han L, Li PT and Li WH designed the research; Du QH, Han L, Jiang JJ, Xu Y and Jia X performed the research; Wang XY contributed new analytic tools; Du QH, Han L and Li WH analyzed the data; and Du QH and Han L wrote the paper.
Supported by Grants from National Key New Drug Creation Project of China, No. 2009ZX09102; and National Natural Science Foundation of China, No. 81273885
Correspondence to: Wei-Hong Li, MD, School of Fundamental Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Beijing 100029, China. liweihong.403@163.com
Telephone: +86-10-64286526
Received: February 17, 2014
Revised: April 18, 2014
Accepted: May 25, 2014
Published online: November 28, 2014
Revised: April 18, 2014
Accepted: May 25, 2014
Published online: November 28, 2014
Core Tip
Core tip: The traditional Chinese medicine Glytan is composed of salvianolic acid B and diammonium glycyrrhizinate. Previous studies have shown that Glytan is a new preparation for portal hypertension. The present study indicated that decreases in portal pressure and portal territory blood flow observed after Glytan treatment in portal hypertensive rats were related to increased mesenteric endothelin-1 content and reduced endothelin B receptor, endothelial NO synthase, G-protein-coupled receptor kinase 2, and β-arrestin 2 expression, which may promote mesenteric vasoconstriction and increase receptor sensitivity to vasoconstrictors. These results suggest the therapeutic potential of Glytan in portal hypertension induced by liver cirrhosis.